Holen Sie sich die Stockscreener-App
18.91
2.20%
0.505
Handel nachbörslich:
18.94
0.025
+0.13%
Schlusskurs vom Vortag:
$18.41
Offen:
$18.45
24-Stunden-Volumen:
451.63K
Relative Volume:
0.72
Marktkapitalisierung:
$829.83M
Einnahmen:
$719.89M
Nettoeinkommen (Verlust:
$98.09M
KGV:
9.3022
EPS:
2.0334
Netto-Cashflow:
$118.98M
1W Leistung:
+5.58%
1M Leistung:
-12.12%
6M Leistung:
-31.23%
1J Leistung:
-23.11%
1-Tages-Spanne:
$18.45
$19.12
1-Wochen-Bereich:
$17.70
$19.11
52-Wochen-Spanne:
$16.64
$31.26
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
Firmenname
Amphastar Pharmaceuticals Inc
Sektor
Telefon
909-980-9484
Adresse
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
Compare AMPH vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
18.82 | 811.75M | 719.89M | 98.09M | 118.98M | 2.0334 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.24 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Herabstufung | Jefferies | Buy → Hold |
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-08-12 | Hochstufung | Needham | Hold → Buy |
| 2025-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-04 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-03-05 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-17 | Eingeleitet | BofA Securities | Neutral |
| 2023-07-25 | Fortgesetzt | Jefferies | Buy |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-07-29 | Eingeleitet | CapitalOne | Overweight |
| 2022-01-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | Eingeleitet | Northland Capital | Outperform |
| 2019-03-13 | Herabstufung | Needham | Buy → Hold |
| 2019-03-13 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-03-13 | Bestätigt | Needham | Buy |
| 2017-12-01 | Bestätigt | Needham | Buy |
| 2017-11-09 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | Bestätigt | Needham | Buy |
| 2017-03-14 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-05-10 | Bestätigt | Needham | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2015-06-19 | Bestätigt | Needham | Buy |
| 2015-06-03 | Eingeleitet | Raymond James | Strong Buy |
| 2014-07-21 | Eingeleitet | Needham | Buy |
Alle ansehen
Amphastar Pharmaceuticals Inc Aktie (AMPH) Neueste Nachrichten
Why Wells Fargo Lowered Amphastar Pharmaceuticals, Inc. (AMPH) Price Target to $19 - Insider Monkey
Amphastar Earnings Call Balances Growth and Margin Strain - TipRanks
Has Amphastar Pharmaceuticals Bottomed Out After Its Steep Decline - Kavout
8 Best Small Cap Pharma Stocks to Buy Right Now - Insider Monkey
Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Lower Today - Yahoo Finance
Amphastar forecasts BAQSIMI revenue flat to up low single digits, with 3% list price increase - MSN
Amphastar Pharmaceuticals Q1 2026: Revenue Miss and Pricing Pressures on BAQSIMI - IndexBox
The 5 Most Interesting Analyst Questions From Amphastar Pharmaceuticals’s Q1 Earnings Call - Yahoo Finance
Pharma Earnings Season 2026: Amphastar Flat, Eli Lilly Surges in Q1News and Statistics - IndexBox
Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment - Yahoo Finance
There May Be Some Bright Spots In Amphastar Pharmaceuticals' (NASDAQ:AMPH) Earnings - simplywall.st
Amphastar Pharmaceuticals' (NASDAQ:AMPH) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Wells Fargo Initiates Amphastar Pharmaceuticals(AMPH.US) With Hold Rating, Announces Target Price $19 - Moomoo
Is Amphastar Pharmaceuticals Inc (AMPH) a Bargain After 5.6% Dro - GuruFocus
Amphastar Shares Fall After Wells Fargo Downgrade - Moomoo
This Whirlpool Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
Amphastar Pharmaceuticals tackles BAQSIMI discount pressure, keeps sales outlook - MSN
Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook - MarketBeat
AMPH: Proprietary and biosimilar pipeline expansion drives growth, anchored by BAQSIMI® and Primatene MIST - TradingView
How The Amphastar Pharmaceuticals (AMPH) Narrative Is Shifting As Targets Fall And New Drugs Launch - Yahoo Finance
Amphastar Pharmaceuticals (NASDAQ:AMPH) Earns Neutral Rating from Piper Sandler - MarketBeat
(AMPH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Amphastar price target lowered to $21 from $25 at Piper Sandler - TipRanks
Earnings Miss: Amphastar Pharmaceuticals, Inc. Missed EPS By 75% And Analysts Are Revising Their Forecasts - Yahoo Finance
Amphastar Pharmaceuticals (AMPH) Margin Compression Reinforces Bearish Narrative Despite Stable Revenue - Sahm
Needham downgrades Amphastar Pharmaceuticals (AMPH) - MSN
Amphastar Pharmaceuticals (NASDAQ:AMPH) Posts Quarterly Earnings Results - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q1 2026 Earnings Call Transcript - Insider Monkey
Amphastar Pharmaceuticals, Inc. $AMPH Shares Purchased by Denali Advisors LLC - MarketBeat
Amphastar Pharmaceuticals (AMPH) Is Up 9.4% After Profit Falls Despite New Drug Launches And Licensing Deals - Yahoo Finance
Amphastar Pharmaceuticals Q1 2026 10-Q: Financial Results, Risk Factors, and Forward-Looking Statements - Minichart
Amphastar Balances Margin Pain With Pipeline Gains - TipRanks
Amphastar Q1 2026 Results: Revenue Growth Fueled by New Launches | May 2026News and Statistics - IndexBox
Amphastar Pharmaceuticals, Inc.Common Stock (Nasdaq:AMPH) Stock Quote - FinancialContent
Amphastar reports Q1 EPS 42c, consensus 71c - TipRanks
Amphastar cut to Hold at Needham after ‘disappointing’ results - TipRanks
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap DownWhat's Next? - MarketBeat
Amphastar Pharmaceuticals (NASDAQ:AMPH) Given "Hold" Rating at Needham & Company LLC - MarketBeat
Amphastar Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
This HubSpot Analyst Turns Bearish; Here Are Top 5 Downgrades For Friday - Benzinga
12 Health Care Stocks Moving In Friday's Intraday SessionAIM ImmunoTech (AMEX:AIM), Akanda (NASDAQ:AKA - Benzinga
Why Amphastar Pharmaceuticals (AMPH) Is Up 9.4% After Profit Squeeze Despite Flat Q1 2026 Sales - simplywall.st
Earnings call transcript: Amphastar’s Q1 2026 earnings miss expectations By Investing.com - Investing.com Canada
Amphastar Pharmaceuticals, Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Amphastar (AMPH) Q1 2026 Earnings Transcript - The Globe and Mail
Compared to Estimates, Amphastar (AMPH) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
Amphastar Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Amphastar Pharmaceuticals (AMPH) Q1 Earnings Lag Estimates - Yahoo Finance
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 CY2026 Sales Expectations, Stock Drops - Yahoo Finance
Amphastar Pharmaceuticals (NASDAQ:AMPH) Q1 Results Miss Estimates, Stock Slides After Hours - ChartMill
Profit falls as costs rise at Amphastar (NASDAQ: AMPH) in Q1 2026 - Stock Titan
Finanzdaten der Amphastar Pharmaceuticals Inc-Aktie (AMPH)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amphastar Pharmaceuticals Inc-Aktie (AMPH) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zhou Rong | SENIOR EVP, PRODUCTION CENTER |
Dec 17 '25 |
Sale |
26.20 |
9,787 |
256,379 |
138,043 |
| Petersen Floyd F. | Director |
Dec 12 '25 |
Sale |
25.92 |
2,426 |
62,888 |
71,368 |
| Petersen Floyd F. | Director |
Dec 11 '25 |
Sale |
25.69 |
1,737 |
44,620 |
73,794 |
5.13%
6.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):